We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

25 analysts have shared their evaluations of Vertex Pharmaceuticals VRTX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...

36,279 people played the daily Crossword recently. Can you solve it faster than others?36,279 people played the daily Crossword recently. Can you solve it faster than others?

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/E/Growth Investor model based on the published ...

VRTX opened at $462.58 on Tuesday. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...